Adrenocortical carcinoma drugs market is anticipated to grow at a significant CAGR during the forecast period. One of the key factors that are primarily driving the growth of the market includes the comparative advantages of novel drugs over chemotherapeutics. Chemotherapeutics such as mitotane can cause major side effects including peripheral neuropathy and seizures. This is expected to increase the use of novel drugs, which show long-term efficacy and potential benefits in patients.
Another key factor driving the market growth includes the rising advancements in imaging techniques for detecting tumors and adrenal lesions. Various imaging techniques with enhanced diagnostic accuracy as a non-invasive approach have been developed for adrenocortical carcinoma. For instance, the multiphase computed tomography technique is one of the latest imaging techniques which can calculate both the absolute percentage and the relative percentage washout, which helps in identifying both benign and malignant lesions of the adrenal gland. Thus, advances in imaging techniques for adrenal tumors is anticipated to fuel the growth of the global adrenocortical carcinoma drugs market during the forecast period.
Some key players operating in the market include Bristol-Myers Squibb Co., Merck & Co., Inc., and Laboratoire HRA-Pharma SAS, among others. These players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in November 2021, Merck announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) for the first-line treatment of patients with radically unresectable, advanced or recurrent esophageal carcinoma in combination with chemotherapy (5-fluorouracil [5-FU] plus cisplatin) based on data from the Phase 3 KEYNOTE-590 trial.
To Request a Sample of our Report on Adrenocortical Carcinoma Drugs Market: https://www.omrglobal.com/request-sample/adrenocortical-carcinoma-drugs-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Bristol-Myers Squibb Co., Merck & Co., Inc., and Laboratoire HRA-Pharma SAS, among others.
Adrenocortical Carcinoma Drugs Market by Segment
By Type
- Chemotherapy
- Targeted therapy
By Application
- Hospital
- Research Institute
- Clinic
- Other
A full Report of Adrenocortical Carcinoma Drugs Market is Available @ https://www.omrglobal.com/industry-reports/adrenocortical-carcinoma-drugs-market
Adrenocortical Carcinoma Drugs Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/adrenocortical-carcinoma-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
